Structure–activity relationship study of human liver microsomes-catalyzed hydrolysis rate of ester prodrugs of MENT by comparative molecular field analysis (CoMFA)
作者:Roberta Bursi、Arijan Grootenhuis、Jaap van der Louw、Jos Verhagen、Marcel de Gooyer、Peter Jacobs、Dirk Leysen
DOI:10.1016/s0039-128x(02)00186-1
日期:2003.3
A series of MENT esters (3-71) was designed, prepared and tested to study the structure-activity relationship (SAR) of the hydrolysis rate with human liver microsomes of these prodrugs. Compounds were obtained covering a wide range of metabolic stability. The results are useful for the proper selection of prodrugs for different pharmaceutical formulations to deliver the potent and prostate-sparing
Oral pharmaceutical preparation having androgenic activity
申请人:Akzona Incorporated
公开号:US04098802A1
公开(公告)日:1978-07-04
The invention relates to an oral pharmaceutical preparation with androgenic activity on the basis of one or more esters of testosterone and/or 5.alpha.-dihydrotestosterone, the ester group of which has been derived exclusively from aliphatic carboxylic acids having 9-16 carbon atoms, preferably 10-12 carbon atoms in combination with a non-steroidal lipoid. The preparation may additionally contain a progestational steroid, an oestrogen or a precursor of an A-aromatic steroid.
Isocyanates and their preparation using hypochlorous acid
申请人:Olin Corporation
公开号:US05319133A1
公开(公告)日:1994-06-07
The present invention relates to a process for preparation of an isocyanate comprising (a) reacting an amide with an aqueous solution of hypochlorous acid in the presence of an water-immiscible organic solvent to produce an N-chloro amide; and (b) reacting said N-chloro amide with a base in the presence of a phase transfer catalyst and a water immiscible organic solvent to produce an isocyanate.
A liquid crystal device in which the liquid crystal material comprises or contains a compound having ferro- electric spontaneous polarisation properties, the compound being of the formula:
Where L is a liquid crystal residue or liquid crystal compatible material having a terminal cyclic structure directly connected to the asymmetric carbon centre C*, R1 is selected from C1-4-alkyl and halogen and R2 is selected from alkyl, alkoxy, alkylthio, halo-alkyl & -alkoxy, alkoxyalkyl, halogeno, alkyl-carbonyl & -carbonyloxy and alkoxy -carbonyl and -carbonyloxy.
Optical active compounds and liquid crystal compositions containing such compounds
申请人:WAKO PURE CHEMICAL INDUSTRIES, LTD
公开号:EP0402110A1
公开(公告)日:1990-12-12
An optical active compound of the formula:
wherein R is alkyl or alkoxy, R* is an optical active alkyl group, X is alkyl or halogen, Y is a single bond
and C* is an asymmetric carbon, is chemically stable and shows or induces large spontaneous polarization and is useful in a chiral liquid crystal composition.